Avanir docosanol 10% cream
This article was originally published in Pharmaceutical Approvals Monthly
Topical treatment for oral-facial herpes is "approvable" May 31. Approval is expected in the third quarter after minor labeling issues are addressed with FDA, the company says. Avanir predicts that docosanol will be the first FDA-approved OTC cold sore product. SmithKline Beecham Consumer Healthcare will market the produc
You may also be interested in...
A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.
FDA has heard from some manufacturers that additional time is needed to meet all of the requirements, “especially during the COVID-19 pandemic.” Prior to the pandemic, agency announced enforcement discretion during 2020 for compliance by firms with more than $10m in annual sales.
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.